Earlier this month, the U.S. Food and Drug Administration (FDA) declined to approve a new class of diabetes medication until its creators, Bristol-Myers Squibb and AstraZeneca, provide more information on the drug's safety.
On the heels of lawsuits against the diabetes drugs Actos, which increased the risk of bladder cancer, and Avandia, which increased the risk of heart attack, the FDA is requiring additional data on dapagliflozin. It may even require new clinical trials to better assess the risks and benefits of the new drug.


